Collagen

Collagen makes up roughly a third of total protein in the human body, forming the structural scaffold of skin, tendons, cartilage, and bone. Supplement companies sell hydrolyzed collagen, collagen broken into smaller peptides, on the claim that eating it improves skin and joints.

The mechanistic case is not fantasy. Oral ingestion of collagen hydrolysate does lead to measurable levels of intact collagen-derived peptides, particularly Gly-Pro-Hyp and Pro-Hyp, in human blood, with Gly-Pro-Hyp reaching plasma concentrations up to roughly 191 nmol/mL at higher doses in one pharmacokinetic study, and some of that Pro-Hyp has been detected in skin tissue in animal models [1]. That establishes a plausible delivery mechanism, small peptides surviving digestion and reaching tissue, not that skin visibly improves as a result. For joints, a 2025 updated systematic review and meta-analysis of 11 RCTs (870 total participants) in knee osteoarthritis found that collagen supplementation significantly improved both function (mean difference -6.46, 95% CI -9.52 to -3.40, p<0.00001) and pain scores (mean difference -13.63, 95% CI -20.67 to -6.58, p<0.00001) compared to placebo [2].

What the evidence does not show, and this matters more than any single positive trial: a 2025 systematic review and meta-analysis of 23 RCTs (1,474 participants) on collagen supplements and skin aging found that, pooling all trials together, collagen significantly improved skin hydration, elasticity, and wrinkles. But when the authors split the same trials by funding source, studies not funded by supplement or pharmaceutical companies showed no effect on any of the three outcomes, while industry-funded studies showed significant effects. High-quality studies alone, regardless of funding, also showed no significant effect in any category; only low-quality studies showed a significant elasticity improvement. The authors' stated conclusion: there is currently no clinical evidence to support the use of collagen supplements to prevent or treat skin aging [3]. That is about as direct a null verdict as this literature produces, and it comes from the same evidence base the positive headline claim is built on.

The osteoarthritis meta-analysis is more encouraging, but the joint-pain literature has its own limitations: heterogeneity across the 11 pooled trials was high (I²=75-88%), the specific pain scale used was not standardized across studies, and most trials used only one commercial collagen product rather than testing dose-response, so no single trial establishes an optimal dose or duration.

No confirmed Blueprint page lists collagen as a standing daily ingredient with a specific verified dose at the time of this review, so no self-experimentation claim from that program is attributed here.

Critics of the skin-collagen industry point directly to the funding-stratified finding: independently funded, high-quality trials of collagen for skin aging found no significant effect, while industry-funded and lower-quality studies did, a pattern that should make anyone weigh the marketing claim against who paid for the study that supports it [3].

The honest takeaway: collagen supplementation has real, meta-analyzed support for knee osteoarthritis pain and function. For skin aging, the best available evidence, once funding bias is accounted for, does not support the claim.

Products with this: Collagen Peptides